Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan Wangfujing, Dongcheng District, Beijing, 100730, China.
Radiat Oncol. 2018 Dec 17;13(1):249. doi: 10.1186/s13014-018-1197-5.
Concurrent chemoradiotherapy (CCRT) is effective in the treatment of locally advanced cervical squamous cell carcinoma (SCC). However, whether treatment outcomes of cervical adenocarcinoma are equivalent to SCC after CCRT has been a topic of debate.
Medical records of cervical cancer patients treated with definitive radiotherapy or CCRT in our institute from January 2011 to December 2014 were reviewed. Patients were treated with intensity modulated radiation therapy combined with intracavitary brachytherapy. Weekly cisplatin was the first line regimen of concurrent chemotherapy. The treatment outcomes of patients with SCC and adenocarcinoma were compared with a multivariate Cox regression model, and log-rank method before and after propensity score matching (1:1).
A total of 815 patients with stage IB-IVA cervical cancer were included, with 744 patients in the SCC group and 71 patients in adenocarcinoma group. The median follow-up period was 36.2 months (range, 1.0-76.2 months). The 3-year overall survival (OS), disease-free survival (DFS), pelvic control and distant control rates of patients in the SCC group and adenocarcinoma group were 85.2 and 75.4% (p = 0.005), 77.5 and 57.3% (p < 0.001), 89.0 and 74.0% (p = 0.001) and 86.0 and 74.4% (p = 0.011), respectively. After multivariate analysis, histology was an independent factor of OS (p = 0.003), DFS (p < 0.001), pelvic control (p = 0.002) and distant control (p = 0.003). With propensity score matching, 71 pairs of patients were selected. After matching, the OS (p = 0.017), DFS (p = 0.001), pelvic control (p = 0.015) and distant control (p = 0.009) of patients with adenocarcinoma were poorer than those of patients with SCC. In subgroup analysis, patients with adenocarcinoma had significantly worse OS and DFS compared with patients with SCC, regardless of treatment with radiotherapy alone or CCRT.
The present study demonstrated that patients with adenocarcinoma of the cervix had poorer OS and DFS than patients with SCC, regardless of treatment with radiotherapy alone or CCRT. New treatment approaches should be considered for cervical adenocarcinoma.
同期放化疗(CCRT)在治疗局部晚期宫颈鳞癌(SCC)方面具有显著疗效。然而,宫颈腺癌患者接受 CCRT 后的治疗效果是否与 SCC 相当,一直是一个存在争议的话题。
本研究回顾性分析了 2011 年 1 月至 2014 年 12 月期间在我院接受根治性放疗或 CCRT 治疗的宫颈癌患者的病历资料。患者接受调强放疗联合腔内近距离放疗。每周顺铂是同期化疗的一线方案。采用多变量 Cox 回归模型和倾向性评分匹配(1:1)前后的对数秩检验方法比较 SCC 组和腺癌组患者的治疗效果。
本研究共纳入 815 例 I B-IVA 期宫颈癌患者,其中 SCC 组 744 例,腺癌组 71 例。中位随访时间为 36.2 个月(范围 1.0-76.2 个月)。SCC 组和腺癌组患者的 3 年总生存率(OS)、无病生存率(DFS)、盆腔控制率和远处控制率分别为 85.2%和 75.4%(p=0.005)、77.5%和 57.3%(p<0.001)、89.0%和 74.0%(p=0.001)和 86.0%和 74.4%(p=0.011)。多因素分析显示,组织学是 OS(p=0.003)、DFS(p<0.001)、盆腔控制(p=0.002)和远处控制(p=0.003)的独立影响因素。经过倾向性评分匹配,共选择了 71 对患者。匹配后,腺癌组患者的 OS(p=0.017)、DFS(p=0.001)、盆腔控制(p=0.015)和远处控制(p=0.009)均较 SCC 组差。亚组分析显示,无论单独放疗或 CCRT 治疗,腺癌患者的 OS 和 DFS 均明显差于 SCC 患者。
本研究表明,无论单独放疗或 CCRT 治疗,宫颈腺癌患者的 OS 和 DFS 均较 SCC 患者差,需考虑为宫颈腺癌患者提供新的治疗方法。